Last reviewed · How we verify
MDV3100 (mdv3100)
MDV3100, also known as enzalutamide, is an androgen receptor inhibitor developed by Pfizer Inc. It is not currently approved by the FDA but is in advanced stages of clinical development for the treatment of prostate cancer. The drug works by blocking the androgen receptor, which is crucial for the growth of prostate cancer cells. Despite its promising efficacy, MDV3100 has shown several side effects, including fatigue, back pain, and hot flushes. Clinical trials have demonstrated its potential to significantly improve survival rates in patients with castration-resistant prostate cancer.
At a glance
| Generic name | mdv3100 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Androgen receptor inhibitor |
| Target | Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant tumor of prostate
- Metastasis from malignant tumor of prostate
Pipeline indications
Common side effects
Key clinical trials
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (PHASE3)
- Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy (PHASE2)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (PHASE1, PHASE2)
- A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. (PHASE3)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (PHASE3)
- A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer (PHASE1, PHASE2)
- Pan Tumor Rollover Study (PHASE2)
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MDV3100 CI brief — competitive landscape report
- MDV3100 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI